The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma.
We investigated the rates of expression of bone morphogenetic protein-2 (BMP-2) in 29 adult patients with high-grade malignant fibrous histiocytoma of soft tissue, using the BMP-2-specific monoclonal antibody, AbH3b2/17, and found that they ranged from 1.9% to 78.9%. The survival at five years of the groups expressing high (> or = 30%) and low (< 30%) levels of BMP-2 was 85.7% and 36.3%, respectively. Multivariable analysis showed that only BMP-2 had prognostic significance for continuous disease-free survival and for overall survival (p < 0.05). Our findings indicate that over-expression of BMP-2 in malignant fibrous histiocytoma of soft tissue is the most reliable prognostic indicator of the parameters assessed.
Asano
N
N
Department of Orthopaedic Surgery, Mie University Medical School, Faculty of Medicine, Tsu-City, Mie Prefecture, Japan.
Yamakazi
T
T
Seto
M
M
Matsumine
A
A
Yoshikawa
H
H
Uchida
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000378:metabolism*; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D012983:Soft Tissue Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis; D016212:Transforming Growth Factor beta; D016896:Treatment Outcome
C525718:BMP2 protein, human; D014408:Biomarkers, Tumor; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D009363:Neoplasm Proteins; D016212:Transforming Growth Factor beta